Loading...
XJPX
4586
Market cap21mUSD
Oct 09, Last price  
58.00JPY
1D
0.00%
1Q
7.41%
Jan 2017
-87.84%
IPO
-98.19%
Name

Medrx Co Ltd

Chart & performance

D1W1MN
XJPX:4586 chart
P/E
—
P/S
26.88
EPS
—
Div yield, %
—
Shrs. gr., 5y
27.03%
Rev. gr., 5y
2.16%
Revenues
128m
-50.34%
547,491,000291,769,000741,381,00087,806,00068,575,00026,285,00037,612,00022,341,000198,212,0008,397,000169,860,000115,092,0008,350,00059,482,00029,534,000257,915,000128,084,000
Net income
-937m
L+16.19%
-166,869,000-536,664,999-433,093,000-571,338,000-621,997,000-1,016,547,000-878,366,000-1,259,081,000-884,387,000-1,267,686,000-1,616,314,000-1,114,645,000-1,059,833,000-1,111,150,000-932,897,000-806,756,000-937,373,000
CFO
-888m
L+10.60%
-492,150,000-322,415,000-535,715,000-613,291,000-931,812,000-789,060,000-1,215,001,000-854,320,000-1,260,847,000-1,546,956,000-985,354,000-923,688,000-1,073,292,000-913,000,000-803,000,000-888,109,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.

Key people

Masayoshi Matsumura
Chairman of the Board · since 2024
Hiroshi Akitomo
Director of Development, Director · since 2005
Ken Fujioka
Director of Business Administration, Director · since 2020
Hidetoshi Hamamoto
Director of Research, Director · since 2011
Yonehiro Matsumura
President, Chief Executive Officer, President of Subsidiary, Representative Director · since 2017
Kunio Iwatani
Independent Director · since 2016
Sachiko Morikawa
Independent Director · since 2024
Noriko Oshiro
Independent Director · since 2024
Yasushi Yamazaki
Independent Director · since 2024
URL
https://www.medrx.co.jp/
IPO date
Feb 13, 2013
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT